Clinical Updatesdifferentiated thyroid cancerlow-risk
Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial
By MedXY|Oct 1, 2025
The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.